New Evidence With BTK Inhibitor Therapy in CLL and MCL From the Pan Pacific Lymphoma Conference 2022

Gain insight from expert perspectives on key studies from the Pan Pacific Lymphoma Conference 2022 covering BTK inhibition in chronic lymphocytic leukemia and mantle cell lymphoma and the potential implications for clinical practice.